Insight

2021 CCO Survey: Life sciences

Sharing client perspectives on compliance imperatives

Amy S. Matsuo

Amy S. Matsuo

Regulatory and ESG Insights Leader, KPMG US

+1 919-664-7100

Ash Shehata

Ash Shehata

Principal, National Sector Leader for HCLS, KPMG US

+1 513-763-2428

Jennifer Shimek

Jennifer Shimek

Principal, Advisory, KPMG US

+1 973-912-6167

The focus is clear: To be more patient centric while facing new regulatory and market pressures

Chief Ethics and Compliance Officers (CCOs) are taking the lead as change agents, advancing their functions, operations, and analytics from responsive to proactive, anticipating shifts in regulatory and stakeholder expectations, and preventing exposures. The KPMG 2021 CCO Survey explores how CCOs are adapting to these new global trends and evolving risks. The life sciences sector is focused on being more patient centric while facing new regulatory and market pressure, yet still being at the forefront of innovative responses to the global pandemic.

See how life sciences CCOs responded to the survey, highlights including:

  • Activities to enhance
  • Obligations to refine
  • Anticipating investments in ethics and compliance
  • Metric effectiveness
  • Priorities for automation
  • Areas of expertise needed
As the Life Sciences industry continues to transform, compliance leaders have an opportunity to leverage innovative technologies to proactively chart the compliance agenda, and drive meaningful enterprise impact.
Ash Shehata, KPMG, National Healthcare & Life Sciences Leader